Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imatinib plus Docetaxel and Cisplatin in Advanced NSCLC
NCT02127372Phase 2Terminated
- Sponsor
- Duke University
- Start
- Nov 2004
- Primary completion
- Jun 2010
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of imatinib in non-small cell lung cancer (NSCLC), sponsored by Duke University. Started Nov 2004; status: terminated.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02127372.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02127372.